Research Information System
Indian Journal of Otolaryngology and Head and Neck Surgery, vol.77, no.2, pp.939-942, 2025 (ESCI, Scopus)
Impaired olfaction negatively impacts nutrition and appetite, particularly gaining more significance in cancer patients for whom nutrition and calorie intake are crucial. In our study, we aimed to investigate the effects of advanced-stage colorectal cancer treatment on olfactory functions. Fourteen patients (78.5% males, n = 11 and 21.5% females, n = 3) scheduled for Anti-VEGF (Bevacizumab) and FOLFOXIRI (folic acid, 5-flourouracyl, irinotecan, oxaliplatin) treatment due to advanced-stage cancer colorectal cancer were voluntarily participated in our study. Objective smell tests were conducted using the Sniffin’s stick battery before the start of treatment. After 3 months, tests were repeated to investigate the treatment’s effects. The average age of participants was 58.4 ± 8.5 years. The mean values of the threshold (T), discrimination (D), identification (I), and total (TDI) scores before treatment were found to be 9.43 ± 3.76, 11.92 ± 2.86, 12.71 ± 1.63, and 34.07 ± 5.79, respectively. After treatment, the mean scores for T, D, I, and TDI were 9.29 ± 3.53, 11.42 ± 2.84, 12.71 ± 1.59, and 33.43 ± 5.88, respectively. Statistically significant decrease was observed in post-treatment D and TDI scores (p = 0.015 and p = 0.035, respectively). FOLFOXIRI combined with Bevacizumab, may affect olfactory functions Informing patients about this aspect before treatment could be beneficial.